130 filings
8-K
FPRX
Five Prime Therapeutics, Inc.
16 Apr 21
Completion of Acquisition or Disposition of Assets
8:38am
8-K
FPRX
Five Prime Therapeutics, Inc.
15 Apr 21
Other Events
4:41pm
8-K
FPRX
Five Prime Therapeutics, Inc.
4 Mar 21
Amgen to Acquire Five Prime Therapeutics for Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class
8:58am
8-K
FPRX
Five Prime Therapeutics, Inc.
15 Jan 21
Results of Operations and Financial Condition
5:00pm
8-K
FPRX
Five Prime Therapeutics, Inc.
15 Jan 21
Other Events
10:06am
8-K
j8iinvck93r
17 Nov 20
Five Prime Announces Closing of Upsized Public Offering of Common Stock
5:05pm
8-K
2vci jrv2w
13 Nov 20
Five Prime Announces Pricing of Upsized Public Offering of Common Stock
5:06pm
8-K
r5hnnywifcuxu7xsj
10 Nov 20
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates
5:19pm
8-K
f575tw
3 Nov 20
Five Prime Therapeutics Reports Third Quarter 2020 Results
4:10pm
8-K
ochwpjlrl8 rcr9irjyp
2 Nov 20
Five Prime to Present First Pre-clinical Data of Anti-CCR8 Antibody FPA157
5:11pm
8-K
dso2ye3ddcohohrp5
4 Sep 20
Entry into a Material Definitive Agreement
12:00am
8-K
xwk3qd
1 Sep 20
Departure of Directors or Certain Officers
6:07am
8-K
sji3g8hif bgr
6 Aug 20
Five Prime Therapeutics Reports Second Quarter 2020 Results
4:31pm
8-K
5g59n
20 May 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
w5wfbt wbw2b
7 May 20
Five Prime Therapeutics Reports First Quarter 2020 Results
4:10pm
8-K
4cliy7
17 Apr 20
Departure of Directors or Certain Officers
4:09pm
8-K
rgdyx
14 Apr 20
Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer
9:06am
8-K/A
itva6p j5
6 Apr 20
Cost Associated with Exit or Disposal Activities
4:06pm
8-K
z1a vk4w183
27 Feb 20
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results
4:11pm
8-K
2gaqar
26 Feb 20
Departure of Directors or Certain Officers
4:05pm